Evidence Explorer · MS-N054

Mindfulness-based programs for fatigue after breast cancer

Family: Mindfulness and psychological supportive care
Clinical question: Do mindfulness-based programs improve cancer-related fatigue in breast-cancer survivors?
Evidence label: Promising pooled evidence, but highly heterogeneous.

Evidence at a glance

• Benefit: A 2025 meta-analysis found lower fatigue after mindfulness-based interventions, with a large pooled standardized effect.
• Certainty: Eleven randomized trials were included overall, but programs and populations varied and statistical heterogeneity was high.
• Risk: Usually low physical risk; difficult thoughts or emotions can surface, and fatigue still needs medical assessment.
• Cancer control: Not studied.

What was studied

A 2025 systematic review identified 11 randomized trials of mindfulness-based interventions in breast-cancer survivors. Ten studies, totaling about 1,262 participants across the review’s fatigue analyses, contributed to the pooled fatigue result. Programs, duration, comparison groups, and follow-up varied.

What the evidence shows

The pooled fatigue estimate favored mindfulness-based programs (standardized mean difference −0.86, 95% CI −1.22 to −0.50), but heterogeneity was high (I²=88%). Sleep quality also favored mindfulness in pooled analysis (mean difference −2.54, 95% CI −3.38 to −1.70). A small earlier pilot randomized 35 survivors with clinically significant fatigue to a seven-week mindfulness-based program or waitlist, illustrating both promise and the limited size of some component trials.

What this does not show: These data do not show an anticancer effect, prevent recurrence, or establish that every mindfulness course produces the pooled result.

Limits and uncertainty

• High heterogeneity means the average effect may not describe a specific program or patient.
• Small trials, incomplete reporting of allocation or blinding, and possible publication bias reduce confidence.
• English- and Chinese-language studies predominated; long-term durability was uncertain.
• Standardized effects are difficult to translate into a single clinically meaningful change for an individual.

Safety and practical context

Mindfulness should not replace evaluation for anemia, infection, endocrine disorders, sleep apnea, pain, medication toxicity, depression, or disease progression. Trauma histories, panic, psychosis, or severe depression may call for a modified, clinician-supported approach rather than unsupervised practice.

Questions for the care team

• Has the fatigue been medically evaluated?
• Which specific program, instructor training, dose, and comparator best match the evidence?
• How will fatigue and sleep be measured?
• What support is available if meditation increases distress?

Sources

• 2025 systematic review and meta-analysis (PMCID PMC12515675)
• Review DOI 10.3389/fonc.2025.1585383
• Pilot randomized trial full text (PMCID PMC4331267)
• Oncology Nursing Society evidence resource

Identifiers: Systematic review PMCID PMC12515675; DOI 10.3389/fonc.2025.1585383; pilot PMCID PMC4331267
Last literature search: October 17, 2026
Record appraised: October 17, 2026

Educational information, not personal medical advice. Decisions about symptoms, supplements, movement, or psychological care during cancer treatment should be made with the oncology team.